cardiovascular
Why Site Selection Matters More Than Protocol Design in Cardiovascular Trials
The Single Decision That Determines Whether Your Cardiovascular Trial Finishes on Time
Most sponsors spend months perfecting their protocol. They debate endpoints, refine inclusion criteria, model sample sizes. All of that matters.
But the decision that most often determines whether a cardiovascular trial finishes on time, on budget, and with clean data has nothing to do with the protocol. It is site selection.
A perfectly designed trial placed at the wrong site will under-enroll, generate queries, and bleed money. A good protocol placed at the right site will recruit ahead of schedule and produce data that holds up under audit.
What Makes a Cardiovascular Trial Site Different
Cardiovascular trials are not like oncology trials where patients actively seek experimental treatment. Cardiac patients often do not know they are candidates for a clinical trial until their interventional cardiologist tells them.
That means enrollment depends almost entirely on the site's existing patient flow, the principal investigator's procedural volume, and the research team's ability to screen and consent in real time, often in a cath lab or pre-procedure setting.
A site that publishes impressive annual procedure numbers but has never run a device trial will struggle with the operational mechanics: coordinating imaging endpoints, managing anticoagulation protocols during follow-up, ensuring echo or angiographic core lab submissions meet the timeline.
The Metrics That Actually Predict Performance
When we evaluate cardiovascular trial sites at Amavita Research Services, we look at five things:
- Monthly procedural volume in the target indication. Not annual. Not estimated. Actual monthly cases documented over the prior 12 months.
- PI experience with the specific device category. A TAVR investigator is not automatically qualified for a peripheral atherectomy trial. The procedural skill may transfer, but the regulatory and endpoint requirements differ.
- Dedicated research coordinator availability. Sites that share coordinators across departments lose patients in the screening funnel. Cardiovascular trials need a coordinator who is physically present in the cath lab workflow.
- IRB turnaround time. A site with a 90-day IRB review cycle adds three months to your startup timeline before a single patient is screened.
- Prior audit history. Sites that have survived an FDA inspection with no 483 observations are operationally mature. Sites that have never been inspected may not be.
The Miami Advantage for Cardiovascular Research
Miami has a unique combination of factors that make it one of the strongest markets for cardiovascular clinical research in the United States.
First, the patient demographics. South Florida has one of the highest concentrations of cardiovascular disease burden in the country, driven by an aging population, high rates of hypertension and diabetes, and a diverse ethnic mix that supports broad generalizability of trial results.
Second, the procedural expertise. Miami is home to interventional cardiologists who trained at and continue to collaborate with the top cardiovascular programs in the world. Dr. William O'Neill, who leads Amavita Research Services as Chief Scientific Officer, pioneered some of the most important innovations in interventional cardiology over the past four decades.
Third, the regulatory infrastructure. Florida has a well-established IRB ecosystem with predictable review timelines, and Miami's research institutions have deep experience with FDA-regulated device and drug trials.
What Sponsors Get Wrong
The most common mistake sponsors make in cardiovascular site selection is optimizing for name recognition instead of operational readiness.
A famous academic medical center with a celebrated cardiology department may look impressive on a site selection spreadsheet. But if that center has a 120-day contracting process, a centralized IRB that meets once a month, and a PI who is committed to three other trials simultaneously, your enrollment will stall.
Meanwhile, a dedicated cardiovascular research site with a focused PI, an embedded coordinator, and a streamlined IRB pathway can have your first patient enrolled in 60 days.
The protocol matters. But the site is where the protocol becomes a trial.
Amavita Research Services: Built for Cardiovascular Trials
Amavita Research Services was founded specifically to address this gap. We are not a general-purpose research site that happens to do cardiology. We are a cardiovascular-first clinical research site in Miami, led by Dr. William O'Neill, with dedicated research infrastructure built around the procedural workflows that cardiac device and drug trials require.
Our capabilities include:
- TAVR, structural heart, and peripheral vascular intervention trials
- Heart failure device and pharmacotherapy studies
- Atherectomy and PAD treatment trials
- GCSA-certified and IAOCR-accredited research operations
- Embedded research coordinators in the procedural workflow
- Direct access to a high-volume cardiovascular patient population
If you are planning a cardiovascular clinical trial and site selection is on your timeline, we should talk.
Visit amavitaresearch.com to learn more about our capabilities and team.